Understanding how a personalized risk prediction tool (VALUE-PERSARC) supports informed treatment decisions of soft-tissue sarcomas patients in daily clinical practice - A mixed methods study.
Anouk A KruiswijkEllen G EngelhardtLisa A E VlugRobert J P van de WalYvonne M SchrageRick L HaasMichiel A J van de SandePerla J Marang-van de MheenLeti van Bodegom-Vosnull nullPublished in: European journal of cancer (Oxford, England : 1990) (2024)
PERSARC was not used to support informed treatment decision-making in STS patients. Integrating RPMs into clinical consultations requires acknowledgement of their benefits in facilitating clinicians' estimation of the expected benefit of adjuvant therapies and information provision to patients, while also considering concerns regarding RPM quality and treatment options' viability.